Attached files

file filename
8-K - Xtant Medical Holdings, Inc.e12123_xtnt-8k.htm

Xtant™ Medical Reports Record Fourth Quarter Revenue of $24.5 million, 10% Growth Compared to Prior Year Period See footnote about the use of pro forma financial information

Fourth Quarter 2016 Highlights:

   • Consolidated total revenue increased 9.9% to a record $24.5 million compared to fourth quarter 2015 revenue of
     
   • $22.3 million Consolidated gross profit increased 17.4% to $17.5 million compared to fourth quarter 2015 gross
     
   • profit of $14.9 million Consolidated gross margins improved to 71.6%, compared to 67.0% reported in the fourth quarter of 2015

 

Full-Year 2016 Highlights:

 

   • Consolidated gross profit increased 10.1% to $62.3 million compared to pro forma 2015 gross profit of
     
   • $56.6 million Consolidated gross margins for the year were 69.2%, compared to pro forma 2015 gross margin of 65.4%

 

BELGRADE, Mont., March 9, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT: XTNT, a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the period ended December 31st, 2016. The Company reported annual revenues of approximately $90.0 million and a net loss for the year of approximately $19.5 million.

Revenue

Consolidated fourth quarter 2016 revenue was approximately $24.5 million, an increase of 9.9% compared to revenue of approximately $22.3 million for the same period during 2015.

Consolidated revenue for the full year 2016 was approximately $90.0 million, compared to pro forma 2015 revenue of approximately $86.5 million, representing an increase of 4.0% over the prior year.

Gross Profit

Consolidated gross profit for the fourth quarter of 2016 was $17.5 million or 71.6% of revenues, compared to gross profit of $14.9 million or 67.0% of revenues for the fourth quarter of 2015.

For the year, gross profit was approximately $62.3 million, compared with pro forma 2015 gross profit of $56.6 million. Gross margin for the year was 69.2%, compared to 2015 pro forma gross margin of 65.4%

Sales and Marketing Expenses

Consolidated fourth quarter 2016 sales and marketing expenses increased to $11.9 million, as compared to sales and marketing expenses of $10.6 million during the same period in 2015. For the quarter, sales and marketing as a percentage of revenues increased slightly to 48.8%, compared to 47.6% in the fourth quarter of 2015.

For the year, sales and marketing expenses increased to $44.1 million for 2016, as compared to pro forma 2015 sales and marketing expenses of $39.3 million. As a percentage of revenues, sales and marketing expenses increased to 48.9% compared to 45.5% reported for the pro forma full year 2015.

General and Administrative Expenses

In the fourth quarter, consolidated general and administrative expenses remained flat at $4.5 million as compared to general and administrative expenses of $4.2 million reported for the same period last year. As a percentage of revenues, general and administrative expenses were 18.3% during the period as compared to 18.9% for the same period during 2015.

2016 general and administrative expenses decreased to $15.8 million as compared with $16.6 million reported for the pro forma period last year. As a percentage of revenues, general and administrative expenses were 17.5% as compared to 19.2% for 2015.

Net Income / Loss

The fourth quarter 2016 consolidated net loss was $4.5 million, compared to the same period a year-ago net income of $11.6 million. The decrease was primarily due to a one-time recording of a deferred tax benefit of $17.5 million that occurred during the fourth quarter 2015.

The fourth quarter 2016 consolidated loss per share of $0.31 compared to earnings per share of $0.97 in the fourth quarter of 2015.

For the full-year 2016, the Company had a net loss of $19.5 million compared to a pro forma net loss of $5.8 million for 2015. Net loss per share for the full-year 2016 was $1.54 a share compared to pro forma net loss per share of $0.65 for 2015.

EBITDA

The Company defines earnings before interest, taxes, depreciation and amortization (“EBITDA”) as net income/loss from operations before depreciation, amortization, impairment charges, non-recurring expenses and non-cash stock-based compensation. Consolidated EBITDA for the fourth quarter of 2016 was a gain of $1.2 million compared to a loss of $350,000 for the same period during 2015.

Full year 2016 EBITDA was a gain of $2.0 million compared to a zero pro forma loss in the prior year.

Financial Liquidity

Cash on hand as of December 31, 2016, was $2.6 million, as compared to $6.4 million as of December 31, 2015. Net working capital as of December 31, 2016 decreased $5.7 million to $17.9 million, as compared to $23.6 million as of December 31, 2015.

Outlook for Full Year 2017

The Company plans to have an immediate focus on operational and cash flow efficiencies throughout 2017. As a result, we have reduced revenue guidance while expanding projected EBITDA margins as we get to the latter part of 2017. The Company’s revised full year 2017 revenue and EBITDA guidance is based on the following:

Stated in 000’s  FY ’15*  FY ’16  2017 Guidance
Revenue  $86,518   $90,003    $96,000 - $98,000 
Growth        4%   6.7% - 8.9% 
EBITDA  ($33)  $2,050    $6,900 - $7,700 
*Pro forma results

 

 

 

Conference Call to be Held March 10, 2017

An accompanying listen-only conference call will be hosted by Carl O’Connell, Chief Executive Officer, and John Gandolfo, Chief Financial Officer, to discuss the results. The call will be held at 10:00 AM ET, on March 10, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference date: March 10, 2017, 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Xtant Medical’s Fourth Quarter 2016 Results Call
Webcast Registration: Click Here

Following the live call, a replay will be available on the Company’s website, www.xtantmedical.com, under “Investor Info.”

Use of Pro Forma Financial Information

On July 31,2015, Bacterin International Holdings, Inc. acquired all of the issued and outstanding stock of X-Spine Systems, Inc. and the combined company was renamed Xtant Medical Holdings, Inc. Except for the financial results for the three months ended December 31,2015, the results presented for the full 2015 year are on a pro forma basis as if the two companies were combined for the periods shown. Certain pro forma adjustments have been made to reflect the impact of the purchase transaction, primarily consisting of amortization of intangible assets with determinable lives and interest expense on long-term debt. In addition, certain historical expenses, such as warrant expense and interest expense associated with debt that was immediately repaid, were eliminated from these pro-forma results. The pro forma information does not necessarily reflect the actual results of operations had the acquisition been consummated at the beginning of the fiscal reporting period indicated nor is it indicative of future operating results. The pro forma information does not include any adjustment for potential revenue enhancements, cost synergies or other operating efficiencies that could result from the acquisition.

Additional information regarding the business combination and its impact on the Company’s financial position will be set forth in the Company’s Form 10-K for the fiscal year ended December 31, 2016, which will be filed with the Securities and Exchange Commission on or about March 30, 2017 and will include the Company’s audited consolidated financial statements as of and for the years ended December 31, 2016 and December 31, 2015

About Xtant™ Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “continue,” “efforts,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “strategy,” “will,” “goal,” “target,” “prospects,” “potential,” “optimistic,” “confident,” “likely,” “probable” or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s ability to successfully integrate the acquisition of X-spine; the ability of the Company’s sales force to achieve expected results; the Company’s ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company’s secured lending facility; the Company’s ability to manage cash flow; the Company’s ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company’s customers to pay and the timeliness of such payments; the Company’s ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company’s ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading “Risk Factors.” The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
COCKRELL GROUP
877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com

 

 

 

XTANT MEDICAL HOLDINGS, INC.

Condensed Consolidated Statements of Operations

Unaudited Actual and Proforma Results

 

   For the Three Months Ended December 31,  For the Year Ended December 31,
   2016 Unaudited  2015 Unaudited  2016 Unaudited  2015 Pro Forma
      % of     % of     % of     % of
   Amount  Revenue  Amount  Revenue  Amount  Revenue  Amount  Revenue
Orthopedic Product Sales  $24,362,237    99.6%  $21,771,750    97.8%  $89,388,145    99.3%  $85,235,170    98.5%
Other   108,621    0.4%   494,072    2.2%   614,591    0.7%   1,282,429    1.5%
Total Revenue   24,470,858    100.0%   22,265,822    100.0%   90,002,736    100.0%   86,517,599    100.0%
                                         
Cost of sales   6,960,634    28.4%   7,353,446    33.0%   27,710,014    30.8%   29,913,686    34.6%
                                         
Gross Profit   17,510,223    71.6%   14,912,376    67.0%   62,292,722    69.2%   56,603,913    65.4%
                                         
Operating Expenses                                        
General and administrative   4,484,419    18.3%   4,201,394    18.9%   15,762,531    17.5%   16,612,883    19.2%
Sales and marketing   11,940,049    48.8%   10,607,475    47.6%   44,055,813    48.9%   39,334,250    45.5%
Research and development   798,198    3.3%   1,027,166    4.6%   3,410,600    3.8%   3,840,958    4.4%
Depreciation and amortization   1,250,436    5.1%   2,019,258    9.1%   4,940,955    5.5%   6,220,316    7.2%
Acquisition and Integration related expenses   131,755    0.5%   1,079,236    4.8%   1,401,367    1.6%   4,935,755    5.7%
Gain from the Extinguishment of Debt   0    0.0%   0    0.0%   0    0.0%   (2,345,019)   -2.7%
Impairment of Assets   0    0.0%   0    0.0%   0    0.0%   233,748    0.3%
Non-cash consulting   0    0.0%   55,296    0.2%   266,721    0.3%   246,165    0.3%
Total Operating Expenses   18,604,856    76.0%   18,989,824    85.3%   69,837,986    77.6%   69,079,056    79.8%
                                         
Net Gain (Loss) from Operations   (1,094,633)   -4.5%   (4,077,448)   -18.3%   (7,545,264)   -8.4%   (12,475,142)   -14.4%
                                         
Other Income (Expense)                                        
Interest expense   (3,287,855)   -13.4%   (2,802,807)   -12.6%   (12,262,750)   -13.6%   (10,948,845)   -12.7%
Change in warrant derivative liability   0    0.0%   348,943    1.6%   716,738    0.8%   270,020    0.3%
Non-cash consideration associated with stock purchase agreement   0    0.0%   0    0.0%   0    0.0%   (558,185)   -0.6%
Other income (expense)   (103,990)   -0.4%   582,123    2.6%   (351,914)   -0.4%   395,006    0.5%
                                         
Total Other Income (Expense)   (3,391,845)   -13.9%   (1,871,740)   -8.4%   (11,897,926)   -13.2%   (10,842,004)   -12.5%
                                         
Net Gain (Loss) from Operations Before Benefit (Provision) for Income Taxes   (4,486,478)   -18.3%   (5,949,188)   -26.7%   (19,443,190)   -21.6%   (23,317,146)   -27.0%
                                         
Benefit (Provision) for Income Taxes                                        
Current   (50,362)   -0.2%   0    0.0%   (50,362)   -0.1%   (65,387)   -0.1%
Deferred   0    0.0%   17,537,408    78.8%   0    0.0%   17,537,408    20.3%
                                         
Net Income (Loss)  $(4,536,840)   -18.5%  $11,588,220    52.0%  $(19,493,552)   -21.7%  $(5,845,125)   -6.8%
                                         
Net Income (loss) per share:                                        
Basic  ($0.31)       $0.97        ($1.54)       ($0.65)     
Dilutive  ($0.31)       $0.97        ($1.54)       ($0.65)     
                                         
Shares used in the computation:                                        
Basic   14,479,201         11,890,104         12,671,685         9,055,483      
Dilutive   14,479,201         11,890,104         12,671,685         9,055,483      

 

 

 

XTANT MEDICAL HOLDINGS, INC.

Condensed Consolidated Statements of Operations

Audited and Unaudited Actual Results

 

   For the Three Months Ended December 31,  For the Year Ended December 31,
   2016 Actual Unaudited  2015 Actual Unaudited  2016 Actual Unaudited  2015 Actual Audited
      % of     % of     % of     % of
   Amount  Revenue  Amount  Revenue  Amount  Revenue  Amount  Revenue
Orthopedic Product Sales  $24,362,237    99.6%  $21,771,750    97.8%  $89,388,145    99.3%  $58,194,249    98.1%
Other   108,621    0.4%   494,072    2.2%   614,591    0.7%   1,151,468    1.9%
Total Revenue   24,470,858    100.0%   22,265,822    100.0%   90,002,736    100.0%   59,345,717    100.0%
                                         
Cost of sales   6,960,634    28.4%   7,353,446    33.0%   27,710,014    30.8%   20,262,728    34.1%
                                         
Gross Profit   17,510,223    71.6%   14,912,376    67.0%   62,292,722    69.2%   39,082,989    65.9%
                                         
Operating Expenses                                        
General and administrative   4,484,419    18.3%   4,201,394    18.9%   15,762,531    17.5%   12,993,307    21.9%
Sales and marketing   11,940,049    48.8%   10,607,475    47.6%   44,055,813    48.9%   28,731,184    48.4%
Research and development   798,198    3.3%   1,027,166    4.6%   3,410,600    3.8%   2,546,362    4.3%
Depreciation and amortization   1,250,436    5.1%   2,019,258    9.1%   4,940,955    5.5%   3,819,588    6.4%
Acquisition and Integration related expenses   131,755    21.8%   1,079,236    4.8%   1,401,367    1.6%   4,935,755    8.3%
Gain from the Extinguishment of Debt   0    0.0%   0    0.0%   0    0.0%   (2,345,019)   -4.0%
Impairment of Assets   0    0.0%   0    0.0%   0    0.0%   233,748    0.4%
Non-cash consulting   0    0.0%   55,296    0.2%   266,721    0.3%   246,165    0.4%
Total Operating Expenses   18,604,856    76.0%   18,989,824    85.3%   69,837,986    77.6%   51,161,091    86.2%
                                         
Net Gain (Loss) from Operations   (1,094,633)   -4.5%   (4,077,448)   -18.3%   (7,545,264)   -8.4%   (12,078,101)   -20.4%
                                         
Other Income (Expense)                                        
Interest expense   (3,287,855)   -13.4%   (2,802,807)   -12.6%   (12,262,750)   -13.6%   (7,733,748)   -13.0%
Change in warrant derivative liability   0    0.0%   348,943    1.6%   716,738    0.8%   270,020    0.5%
Non-cash consideration associated with stock purchase agreement   0    0.0%   0    0.0%   0    0.0%   (558,185)   -0.9%
Other income (expense)   (103,990)   -0.4%   582,123    2.6%   (351,914)   -0.4%   388,177    0.7%
                                         
Total Other Income (Expense)   (3,391,845)   -13.9%   (1,871,740)   -8.4%   (11,897,926)   -13.2%   (7,633,736)   -12.9%
                                         
Net Gain (Loss) from Operations Before Benefit (Provision) for Income Taxes   (4,486,478)   -18.3%   (5,949,188)   -26.7%   (19,443,190)   -21.6%   (19,711,838)   -33.2%
                                         
Benefit (Provision) for Income Taxes                                        
Current   (50,362)   -0.2%   0    0.0%   (50,362)   -0.1%   0    0.0%
Deferred   0    0.0%   17,537,408    78.8%   0    0.0%   17,537,408    29.6%
                                         
Net Income (Loss)  $(4,536,840)   -18.5%  $11,588,220    52.0%  $(19,493,552)   -21.7%  $(2,174,430)   -3.7%
                                         
Net Income (loss) per share:                                        
Basic  ($0.31)       $0.97        ($1.54)       ($0.24)     
Dilutive  ($0.31)       $0.97        ($1.54)       ($0.24)     
                                         
Shares used in the computation:                                        
Basic   14,479,201         11,890,104         12,671,685         9,055,483      
Dilutive   14,479,201         11,890,104         12,671,685         9,055,483      

 

 

 

XTANT MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the Twelve months ended
December 31,
   2016 Unaudited  2015 Audited
Operating activities:          
Net loss  $(19,493,552)  $(2,174,430)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   7,241,870    4,889,272 
Purchase accounting valuation allowance   0    (17,537,408)
Non-Cash Interest   6,784,785    4,814,506 
Impairment of Assets   0    956,395 
Gain (Loss) on sale of fixed assets   25,458    (596,883)
Non-cash consulting expense/stock option expense   522,987    836,741 
Provision for losses on accounts receivable and inventory   223,538    700,234 
Change in derivative warrant liability   (716,738)   (270,020)
Non-cash consideration associated with stock purchase agreement   0    558,185 
Extinguishment of debt   0    (2,345,019)
Changes in operating assets and liabilities:          
Accounts receivable   (2,680,405)   (5,512,429)
Inventories   (4,074,086)   (545,713)
Prepaid and other assets   (484,061)   (1,044,962)
Accounts payable   319,091    644,149 
Accrued liabilities   (2,076,183)   7,527,514 
Net cash used in operating activities   (14,407,296)   (9,099,868)
           
Investing activities:          
Acquisition of X-spine Systems, Inc.   0    (72,975,200)
Purchases of property and equipment and intangible assets   (5,832,690)   (2,263,033)
Proceeds from sale of fixed assets   16,400    1,667,195 
Net cash used in investing activities   (5,816,290)   (73,571,038)
           
Financing activities:          
Proceeds from long-term and convertible debt, net of deferred and financing costs   3,238,166    83,897,361 
Net proceeds from equity private placement   0    515,395 
Payment on royalty obligation   0    (542,905)
Payments on Long-term debt   0    (1,325,814)
Payments on capital leases   (144,600)   (101,760)
Net proceeds from the issuance of stock   3,087,462    2,116,937 
Net Proceeds from the revolving line of credit   10,252,809    0 
Proceeds from exercise of options   0    11,500 
Net cash provided by financing activities   16,433,837    84,570,714 
           
Net change in cash and cash equivalents   (3,789,749)   1,899,808 
Cash and cash equivalents at beginning of period   6,368,016    4,468,208 
Cash and cash equivalents at end of period  $2,578,267   $6,368,016 

 

 

 

XTANT MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of December 31, 2015 and 2016

 

  As of   As of
  Dec. 31, 2016
Unaudited
  Dec. 31, 2015
Audited
ASSETS          
Current Assets:          
Cash and cash equivalents $ 2,578,267   $ 6,368,016
Trade accounts receivable, net of allowance for doubtful accounts of $1,635,385 and $2,579,634, respectively   18,991,872     15,385,218
Inventories, net   26,266,457     22,684,716
Prepaid and other current assets   1,149,616     601,697
Total current assets   48,986,211     45,039,647
           
Non-current inventories   971,854     1,607,915
Property and equipment, net   15,840,730     11,816,629
Goodwill   41,534,626     41,534,626
Intangible assets, net   35,940,810     40,237,289
Other assets   827,372     791,221
Total Assets $ 144,101,605   $ 141,027,327
           
LIABILITIES & STOCKHOLDERS’ (DEFICIT) EQUITY          
Current Liabilities:          
Accounts payable $ 10,471,944   $ 9,386,531
Accounts payable - related party   640,441     1,406,763
Accrued liabilities   8,982,187     9,595,851
Revolving Line of Credit   10,448,283     0
Warrant derivative liability   333,613     1,050,351
Current portion of capital lease obligations   244,847     35,139
Total current liabilities   31,121,316     21,474,635
Long-term Liabilities:          
Capital lease obligation, less current portion   832,152     7,800
Long term convertible debt, less current portion   68,937,247     66,436,647
Long-term debt, less current portion   50,284,187     44,231,718
Total Liabilities   151,174,902     132,150,800
           
Commitments and Contingencies          
Stockholders’ Equity          
Preferred stock   -     -
Common stock   17     11
Additional paid-in capital   85,461,210     81,917,488
Accumulated deficit   (92,534,524)     (73,040,973)
Total Stockholders’ Equity (Deficit)   (7,073,297)     8,876,527
           
Total Liabilities & Stockholders’ Equity $ 144,101,605   $ 141,027,327

 

 

 

XTANT MEDICAL HOLDINGS, INC.

Calculation of Consolidated EBITDA for the Three and Twelve Months Ended December 31, 2016

and for the Three and Pro Forma Twelve Months Ended December 31, 2015

Unaudited

 

   For the three months ended December 31,  For the twelve months ended December 31,
   2016  2015  2016  2015
Net Loss   (4,536,840)   11,588,220    (19,493,552)   (5,845,125)
                     
(Benefit) Provision   50,362    (17,537,408)   50,362    (17,472,021)
Other (Income) Expense   103,990    (582,123)   351,914    (395,006)
Change in warrant derivative liability   0    (348,943)   (716,738)   (270,020)
Non-cash consideration associated with stock purchase agreement   0    0    0    558,185 
Interest expense   3,287,855    2,802,807    12,262,750    10,948,845 
Acquisition and Integration related expenses   131,755    0    1,401,367    233,748 
Extinguishment of Debt   0    1,079,236    0    4,935,755 
Impairment of Assets   0    0    0    (2,345,019)
Non-Cash Compensation   0    163,124    522,987    794,358 
Depreciation & Amortization   1,690,020    2,485,321    7,241,870    8,822,994 
One Time Inventory Reserves and Accounts Receivables Allowances   426,355    0    426,355    0 
EBITDA Gain (Loss)   1,153,497    (349,767)   2,047,315    (33,306)